Acetylsalicylic acid/atorvastatin/ramipril

Acetylsalicylic acid/atorvastatin/ramipril
Combination of
Acetylsalicylic acidAntiplatelet
AtorvastatinStatin
RamiprilACE inhibitor
Names
Trade namesIltria, Trinomia, Sincronium, others[1][2]
Clinical data
Main usesPrevention of heart disease and stroke[3]
Side effectsThose of the individual components[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽

Acetylsalicylic acid/atorvastatin/ramipril, also known as aspirin/atorvastatin/ramipril, is a combination medication used to prevent heart disease and stroke.[3] Following a heart attack it decreases the risk of death from heart disease by about a third.[2] It is taken by mouth.[4] The combination is easier to take for some people than the individual components.[4]

Side effects are those of the individual components.[1] It is a combination of acetylsalicylic acid (aspirin), an antiplatelet; atorvastatin, a statin; and ramipril, a ACE inhibitor.[1]

The combination was approved for medical use in parts of Europe and Latin America in 2014.[1][5] As of 2023 it was available in 25 countries.[2] It is not available in the United States as of 2023.[2] It is on the World Health Organization's List of Essential Medicines.[6] Alternative may be manufactured with different statins or ACE inhibitors.[4] The components are generally generic medicines.[4] It is a type of polypill.[7] It costs about €10 to €40 a month as of 2016.[5]

References

  1. 1 2 3 4 5 "Iltria" (PDF). HAS. June 2016. Archived (PDF) from the original on 9 September 2023. Retrieved 8 September 2023.
  2. 1 2 3 4 "World Health Organization Includes the Cardiovascular Polypill in Its List of Essential Medicines After a Groundbreaking Study Led by the President of Mount Sinai Heart | Mount Sinai - New York". Mount Sinai Health System. Archived from the original on 10 August 2023. Retrieved 24 September 2023.
  3. 1 2 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 9 September 2023. Retrieved 8 September 2023.
  4. 1 2 3 4 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 9 September 2023. Retrieved 8 September 2023.
  5. 1 2 "Cardiovascular Polypill" (PDF). Wellcome Trust. 2016. Archived (PDF) from the original on 4 February 2023. Retrieved 24 September 2023.
  6. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  7. ↑ "'Polypill' helps reduce cardiovascular deaths after heart attack". www.medicalnewstoday.com. 2 September 2022. Archived from the original on 29 May 2023. Retrieved 24 September 2023.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.